Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Content zoeken bij Prinses Máxima Centrum
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma
Marc Remke
, Thomas Hielscher
, Andrey Korshunov
, Paul A. Northcott
, Sebastian Bender
,
Marcel Kool
, Frank Westermann
, Axel Benner
, Huriye Cin
, Marina Ryzhova
, Dominik Sturm
, Hendrik Witt
, Daniel Haag
, Grischa Toedt
, Andrea Wittmann
, Anna Schöttler
, André O. Von Bueren
, Andreas Von Deimling
, Stefan Rutkowski
, Wolfram Scheurlen
Andreas E. Kulozik, Michael D. Taylor, Peter Lichter, Stefan M. Pfister
Toon overzicht 4 andere
Toon minder
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
Onderzoek
›
peer review
151
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Poor Prognosis
100%
Follistatin
100%
Sonic Hedgehog Medulloblastoma
100%
Medulloblastoma
71%
Tumor
42%
Sonic Hedgehog
42%
High Risk
28%
Dismal Prognosis
28%
Immunopositivity
28%
Genetic Modification
14%
Clinical Trials
14%
Expression Pattern
14%
Intermediate Risk
14%
Patient Cohort
14%
Immunohistochemistry
14%
Genomic Approaches
14%
Prognostic Value
14%
Treatment Stratification
14%
Effective Treatment
14%
Quantitative PCR
14%
Transcriptome
14%
Medulloblastoma Subgroups
14%
Large Cohort
14%
Integrated Genomics
14%
Copy number Analysis
14%
Early Treatment
14%
DNA Copy number
14%
Good Prognosis
14%
Marker Genes
14%
Molecular Subgroups
14%
Clinical Heterogeneity
14%
Non-overlapping
14%
Risk for Relapse
14%
Molecular Biomarkers
14%
Tissue Microarray
14%
Prognostic Power
14%
Bioinformatics Tools
14%
Cost-effective Tool
14%
Molecular Subgrouping
14%
Molecular Variants
14%
Stable Groups
14%
Differentially Expressed Transcripts
14%
Screening Population
14%
Epitranscriptomic Modification
14%
Molecular Stratification
14%
Medicine and Dentistry
Medulloblastoma
100%
Follistatin
100%
Sonic Hedgehog Protein
100%
Tumor
42%
Transcriptome
14%
Clinical Trial
14%
Biological Marker
14%
Gene Mutation
14%
Immunohistochemistry
14%
Health Care Cost
14%
Transcriptomics
14%
Real-Time Polymerase Chain Reaction
14%
Prognostication
14%
Gene Dosage
14%
Biological Product
14%
Tissue Microarray
14%
Marker Gene
14%
Genetics
14%
Effective Treatment
14%
Neuroscience
Medulloblastoma
100%
Sonic Hedgehog
100%
Follistatin
100%
Transcriptome
14%
Transcriptomics
14%
Immunohistochemistry
14%
Real-Time Polymerase Chain Reaction
14%
Gene Dosage
14%
Gene Mutation
14%
Marker Gene
14%
Genetics
14%
Biological Marker
14%
Biochemistry, Genetics and Molecular Biology
Follistatin
100%
Sonic Hedgehog
100%
Clinical Trial
14%
Gene Mutation
14%
Transcriptomics
14%
Copy Number Analysis
14%
Gene Dosage
14%
Real-Time Polymerase Chain Reaction
14%
Marker Gene
14%
Tissue Microarray
14%
Genomics
14%
Transcriptome
14%
Bioinformatics
14%